Insider Buying: Seaport Therapeutics (NASDAQ:SPTX) Director Buys $235,820.00 in Stock

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Director Robert Hombach acquired 13,000 shares of Seaport Therapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was acquired at an average price of $18.14 per share, with a total value of $235,820.00. Following the completion of the purchase, the director directly owned 13,000 shares in the company, valued at $235,820. This represents a ? increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Seaport Therapeutics Price Performance

Shares of SPTX stock opened at $18.97 on Wednesday. Seaport Therapeutics, Inc. has a 1 year low of $14.85 and a 1 year high of $23.00.

Seaport Therapeutics (NASDAQ:SPTX) last posted its quarterly earnings results on Monday, June 8th. The company reported ($10.34) EPS for the quarter, topping analysts’ consensus estimates of ($10.64) by $0.30.

Analysts Set New Price Targets

Several research analysts have commented on SPTX shares. Leerink Partners assumed coverage on Seaport Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $35.00 target price for the company. Wall Street Zen raised shares of Seaport Therapeutics to a “hold” rating in a report on Saturday, May 9th. Seaport Research Partners set a $42.00 price target on shares of Seaport Therapeutics in a report on Tuesday, May 26th. JPMorgan Chase & Co. initiated coverage on shares of Seaport Therapeutics in a research report on Tuesday, May 26th. They issued an “overweight” rating and a $42.00 price objective for the company. Finally, UBS Group cut shares of Seaport Therapeutics to a “sell” rating in a research note on Tuesday, June 9th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Seaport Therapeutics presently has a consensus rating of “Hold” and an average target price of $35.50.